US-based biotechnology firm Leap Therapeutics has entered an immunotherapy collaboration with Belgian European Organisation for the Research and Treatment of Cancer (EORTC) to conduct a clinical trial of DKN-01 to treat advanced biliary tract cancers.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

To be sponsored by EORTC, the trial will include a combination of DKN-01 with Roche’s atezolizumab (Tecentriq) with or without addition of paclitaxel.

Being developed as both a monotherapy and a combination therapy, DKN-01 is a humanised monoclonal antibody designed to target the Dickkopf-1 (DKK1) protein.

Set to commence enrolment next year at various EORTC centres in Europe, the trial will assess the efficacy and safety of the Wnt-targeted therapy and immune checkpoint inhibitor combination with and without chemotherapy.

"We look forward to expanding our clinical studies into Europe with the support of the EORTC Gastrointestinal tract cancer Group (GITCG)."

Leap Therapeutics clinical development vice-president Cynthia Sirard said: “We look forward to expanding our clinical studies into Europe with the support of the EORTC Gastrointestinal tract cancer Group (GITCG).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“This immunotherapy collaboration further expands our vision as we look to build upon the foundational activity we have seen with DKN-01 and backbone chemotherapy in these malignancies with significant unmet medical need.”

Reported to have shown single agent activity for treatment of non-small-cell lung cancer, DKN-01 is being further studied in an investigator-initiated trial to treat patients with hepatocellular carcinoma.

The firm is also evaluating its product candidate in combination with gemcitabine and cisplatin for biliary tract cancer, and alone as well as in combination with paclitaxel for esophagogastric cancer.

Image: CT of oesophageal cancer. Photo: courtesy of Tdvorak.